2 completed, 1 recruiting, 1 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow Refractory Primary Peritoneal Carcinoma: new trials by email Literature Review of Refractory Primary Peritoneal Carcinoma trials Research Report on Refractory Primary Peritoneal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Irinotecan Sucrosofate - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Completed | Northwestern University | 3 | 2021-03-16 | 2023-01-19 |
| ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer Akt/ERK Inhibitor ONC201, Paclitaxel, Questionnaire Administration - Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | Recruiting | Ira Winer | 62 | 2020-01-21 | 2026-06-17 |
| AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Batiraxcept, Durvalumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 12 | 2019-12-03 | 2025-06-11 |
| Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Durvalumab, Tremelimumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 100 | 2017-05-18 | 2026-08-05 |
Fallopian Tube Neoplasms (4) · Ovarian Neoplasms (4)
Adnexal Diseases (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Fallopian Tube Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Gonadal Disorders (4) · Neoplasms (4) · Neoplasms by Site (4) · Ovarian Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4)
Disulfides (3) · Immunoglobulin G (3) · durvalumab (2) · AVB-500 fusion protein (1) · Bevacizumab (1) · Esters (1) · Paclitaxel (1) · TIC10 compound (1) · Taxes (1) · irinotecan sucrosofate (1) · tremelimumab (1)
M.D. Anderson Cancer Center (2) · Ira Winer (1) · Northwestern University (1)
United States (4)
Amir A Jazaeri (2) · Daniela E Matei, M.D. (1) · Ira Winer, M.D. (1)
P30CA060553 (1)